Novadip: Results from Novadip phase 1b/2a trial reveal 88% efficacy

Novadip Biosciences, a clinical stage biotechnology company with a specialty in regenerative medicine, has announced the results of its 12-month post-surgical visit as part of phase 1b/2a of the NCT05693558 trial. The trial is to monitor the results of an investigational tissue regeneration product from Novadip, NVD003. The product is derived from adipose stem cells [...] The post Results from Novadip phase 1b/2a trial reveal 88% efficacy appeared first on Pharmafile.